Introduction
Antiretroviral treatment and drug resistance testing guidelines indicate a plasma HIV-1 RNA load level of 500-1000 copies/mL as the recommended threshold for drug resistance testing. 1, 2 This threshold has been defined by the detection limits of commercial assays and early clinical experience. Currently, several laboratories have improved the performance of their resistance testing protocols, thereby increasing the success of amplification and sequencing at viral load levels ,1000 copies/mL. 3 -10 We report here the influence of plasma HIV-1 RNA levels on the probability of detecting major drug resistance mutations (DRMs) 
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CD4 count (cells/mm 3 ) >500K Unknown Figure 1 . Distribution of HIV-1 RNA load and CD4 T cell counts contemporary to the sequencing date in our study population (n¼16511).
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Italy, Portugal, Spain, Sweden and the UK. The main aim of SEHERE is to characterize the epidemiologic patterns of acquired HIV-1 drug resistance in Europe. 15, 16 A preliminary analysis of the dataset showed that the viral load at the time of testing influenced the detection of drug resistance by genotypic testing. 15 Furthermore, a recent study from the UK HIV Drug Resistance Database reported a good yield of drug resistance testing at low viral load levels. 9 The aim of this study was to extend the previous observations by analysing a large cohort reflecting European practice and to characterize the influence of viral load strata ,1000 copies/mL on the detection of antiretroviral drug resistance. It has been previously shown that heavily pre-treated patients who remain on a partially suppressive regimen have a measurable risk of losing future drug options, particularly those patients who have few baseline mutations. This analysis will also focus on patients who have been exposed to antiretroviral therapy (ART) for .6 months.
17,18
Methods
Study population
HIV-1 pol (reverse transcriptase and polymerase) gene sequences performed after 1999 and before 2009 were extracted from the SEHERE, a combined database of resistance test results obtained in routine clinical care in seven countries (Italy, the UK, Portugal, Germany, Belgium, Sweden and Spain). Eligible patients were on ART at the time of resistance testing (where ART had started and been uninterrupted for ≥6 months before), and had undergone measurement of their plasma HIV-RNA load (with ultrasensitive methodology) and CD4 T cell count within 30 days prior to the date of resistance testing. Patients who were treatment experienced but had discontinued therapy at the time of testing were not included. In case of multiple tests being available, only one genotype per patient per year was retained, unless the patient was being administered a different ART. For each patient, demographics and clinical information were obtained. Control groups comprised ART-naive patients at the time of resistance testing.
This research was conducted in accordance with the Declaration of Helsinki, and national and institutional standards. Each study cohort was responsible for Ethics Committee approvals, written informed consent gathering from study participants and privacy protection.
Definitions
We defined resistance to an antiretroviral drug class as the presence of at least one DRM included in the mutation list panelled by the International AIDS Society in 2009, 19 considering the nucleos(t)ide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). For the latter, only major DRMs were considered. In addition, resistance to at least one, at least two and three drug classes was defined as the presence of at least one, two or three DRMs affecting the susceptibility to the same antiretroviral drug classes. Mutations were annotated as amino acid changes with respect to the HIV-1 subtype B consensus sequence, with an in-house modified version of the Smith-Waterman-Gotoh local pair-wise alignment algorithm, 20 which is implemented and routinely used in the EuResist study cohort. 11 We defined as 'other mutations' all the amino acid changes from consensus B that were not listed as major or minor resistance mutations by the International AIDS Society in 2009. 19 
Statistical analyses
Multivariable logistic regression was employed to identify predictors of resistance to NRTIs, NNRTIs, PIs, and to at least one, at least two and three antiretroviral classes, with a focus on the viral load level at the time of resistance testing. The latter was stratified in the categories of ≤50, 51-200, 201-500, 501-1000, 1001 -10 000, 10 001-100000 and .100000 copies/mL.
In order to account for multiple patients' observation at different timepoints, generalized estimating equations were used. 21, 22 Univariable Poisson regression models were fitted on the number of DRMs and other mutations with respect to different viral load strata, in both ART-experienced and ART-naive patients.
Covariates analysed at the time of resistance testing were as follows: patients' age; gender; country of origin (grouped as Italy, Portugal, the UK and other); mode of HIV-1 transmission (heterosexual, male Table 1 for categories); previous usage of NRTIs, NNRTIs, PIs or other antiretroviral drug classes; number of previous ART changes (considering any drug change for any reason); previous administration of a suboptimal ART regimen (fewer than three drugs in a regimen, except for ritonavir-boosted PI regimens); and total ART duration.
The R language and environment for statistical computing, with the library geepack, was the software chosen for all statistical analysis. 24 
Results
A total of 16511 resistance test results from 11492 treatment-experienced patients met the study inclusion criteria. Table 1 illustrates the patients' demographic and clinical characteristics, and the prevalence of drug resistance. The proportion of resistance tests performed at a viral load level ,1000 copies/mL was 2500/16 511 (15.14%). Figure 1 details the distribution of viral load and CD4 T cell counts at the time of genotyping.
The crude distribution of drug resistance according to viral load is illustrated in Figure 2 . The prevalence of any resistance to NRTIs/NNRTIs/PIs, and to at least one, at least two and three drug classes varied significantly by the viral load strata (P,0.0001 for all). There was a clear trend for resistance to increase at higher viral load levels, with a peak in the 1001-10000 copies/mL stratum for NRTI resistance and in the 10 001-100 000 copies/mL stratum for NNRTI/PI resistance, followed by a decrease in the highest viral load stratum.
These findings were confirmed by multivariable analyses, adjusting among other factors by cohort, viral subtype, age, calendar year, current ART and treatment history. There was an independent association between viral load and the odds of detecting drug resistance of any type and to any of the three drug classes examined (Tables 2 and 3 ). The adjusted analysis showed progressively declining trends for the odds ratios of detecting drug resistance with declining viral load, as compared with the reference stratum of 1001-10000 copies/mL to each individual class and combination of drug classes. Conversely, there was no measurable effect of CD4 T cell counts on the odds of detecting drug resistance. Of note, a more recent calendar year was strongly associated with a decline in the odds of detecting drug resistance of any type and to any of the three drug classes examined. A further analysis was performed in order to verify whether the reduction in the odds of detecting DRMs with declining viral load levels was due to an impaired sensitivity of current genotyping technologies when processing plasma with low HIV-1 RNA copies. For this purpose, we considered a single sequence per patient (the most recent) from our study population, corresponding to n¼5706 subtype B and n¼ 3736 different non-B subtypes. As a control group, we considered a set of subtype B and non-B sequences from ART-naive patients enrolled in SEHERE (n ¼1416 subtype B and n¼1749 non-B). We counted the number of DRMs in different viral load strata in the populations of ART-naive and ART-experienced patients. Overall, the median [interquartile range (IQR)] number of DRMs observed in the subtype B ART-naive population was 0 (0 -0), whilst that of the population exposed to ART for .6 months was 3 (1 -7). When considering non-B subtype sequences, the corresponding median (IQR) number of DRMs were 0 (0 -0) and 2 (0 -5) in the same ART strata. Figures S1 and S2 (available as Supplementary data at JAC Online) depict the average number and prevalence [95% confidence interval (CI)] HIV-1 drug resistance at low viral load levels 1891 JAC of DRMs and other mutations by increasing viral load strata in the different ART groups, according to subtype. In univariable Poisson regression (Table 4) , the relative risk of detecting a higher number of DRMs in the subtype B ART-experienced population increased from viral load levels of 50 -1000 copies/mL (from 0.52 to 0.84, P,0.0001 for all) and decreased at HIV-1 RNA .10 000 copies/mL (from 0.96 to 0.83, max P ¼ 0.0117). When considering the frequency of other mutations, a lower risk was observed for viral load strata ,1000 copies/mL (from 0.83 to 0.92, P,0.0001 for all) and a slightly increased risk was observed at HIV-1 RNA .10 000 copies/mL (from 1.02 to 1.04, max P ¼0.00771). Results for non-B subtypes were similar. In the ART-naive population, the different viral load strata did not always show statistically significant changes in the risk of detecting different numbers of DRMs or other mutations, both in the subtype B and non-B sequences. In subtype B isolates, the highest HIV-1 RNA strata (.10 000 copies/mL) showed a lower risk of detecting DRMs as compared with the reference stratum of 1000-10000 copies/mL (from 0.49 to 0.37, P,0.0001). Also, the relative risk of detecting DRMs from viral load levels of 50 -1000 copies/mL was low, from 0.58 to 0.82, with a significant (P ¼ 0.00261) reduction of 0.22 only in the HIV-1 RNA stratum of 401 -500 copies/mL. However, the results were not confirmed when considering the non-B isolates (Table 4) .
Discussion
This study aimed at evaluating the prevalence of DRMs in sequences sampled from ART-experienced patients in relation to the plasma HIV-1 RNA load measured at the time of resistance testing, in a large European multicentre cohort. Results indicate that patients with very high or very low viral load levels (as compared with the 1000-10 000 copies/mL stratum) show fewer DRMs, independently from other measurable confounders, including drug exposures at the time of testing. Our findings are in accordance with a previous study conducted in the UK, 9 whose study population has been included in SEHERE, and projects those results to different European contexts.
One limitation of this study is that the heterogeneity of ART combinations was encoded using simple adjustment factors (current ART and previous drug class exposures), without accounting for possible variable interactions or stratifying the models by therapy lines/combinations, whilst different ART courses would be expected to have a substantial role in determining the different prevalence of DRMs at low viral loads. 25 -27 The ability of current genotyping techniques to successfully detect DRMs both at low and high HIV-1 RNA loads 3 -10 was confirmed by our analysis. In a parallel analysis, we found also that in ART-exposed patients (both subtype B and non-B isolates) the relative risk of detecting a higher number of DRMs increased from viral load levels of 50-1000 copies/mL and decreased at HIV-1 RNA .10000 copies/mL. The finding of decline in the prevalence of DRMs at the very high viral load strata in ART-experienced individuals is compatible with a lower medication adherence in these cases, with lower pharmacological exposure determining less drug resistance selection. 28 Conversely, the relative risk of detecting a higher number of other mutations consistently increased per higher viral load levels. This is in line with a higher probability of mutant selection with increased viral replication under drug selective pressure. These trends were also observed in the ART-naive population (subtype B isolates), although they could not be always confirmed at the 95% confidence level. In addition, in the non-B subtype population, the statistical significance of the results was even lower (but this could be due to a smaller sample size for each viral load stratum). This may, anyway, suggest that in ART-naive patients low viral load is not necessarily associated with a lower probability of detecting viral mutants per se, as it was clearly observed in the ART-exposed population.
These findings have relevant clinical application, since they confirm that genotyping tests at low viral loads, although associated with less drug resistance, report results reasonably reliable even at lower viral load strata. However, the detection of drug resistance at low viral load levels is substantial. This should encourage laboratories to set in place novel techniques in order to be able to genotype resistance at low viral loads (,500 copies/mL) and, therefore, to prevent the accumulation of new resistance-associated mutations before being able to perform a viral genotype-guided treatment modification.
In conclusion, genotyping at low viral load may identify HIV-1 resistance at earlier stages of development and, thus, might be successfully employed when evaluating early treatment switch strategies, in order to prevent the development of drug resistance, and preserve the currently available and future treatment options.
